OLMA
What one share of Olema Pharmaceuticals holds
Pharmaceutical Preparations
Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.
Olema Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.13 |
|---|---|
| Cash and investments | $5.27 |
| Book value | $4.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$1.66 | — | −$1.19 | — | −$4.09 |
| 2020 | — | −$3.42 | $0.01 | −$2.84 | — | — |
| 2021 | — | −$1.80 | $0.04 | −$1.32 | — | $7.15 |
| 2022 | — | −$2.62 | $0.01 | −$2.06 | — | $4.90 |
| 2023 | — | −$2.14 | — | −$1.85 | — | $4.62 |
| 2024 | — | −$2.20 | $0.00 | −$1.78 | — | $5.50 |
| 2025 | — | −$1.87 | — | −$1.69 | — | $5.88 |